Jan Stahlberg Acquires 208,872 Shares of DiaMedica Therapeutics (NASDAQ:DMAC) Stock

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) major shareholder Jan Stahlberg bought 208,872 shares of DiaMedica Therapeutics stock in a transaction dated Friday, November 21st. The stock was acquired at an average cost of $7.41 per share, with a total value of $1,547,741.52. Following the transaction, the insider owned 8,712,390 shares of the company’s stock, valued at $64,558,809.90. This trade represents a 2.46% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Jan Stahlberg also recently made the following trade(s):

• On Tuesday, November 25th, Jan Stahlberg bought 73,099 shares of DiaMedica Therapeutics stock. The shares were acquired at an average price of $8.57 per share, for a total transaction of $626,458.43.
• On Monday, November 24th, Jan Stahlberg bought 40,253 shares of DiaMedica Therapeutics stock. The shares were acquired at an average cost of $7.89 per share, for a total transaction of $317,596.17.
• On Thursday, November 20th, Jan Stahlberg purchased 128,426 shares of DiaMedica Therapeutics stock. The stock was acquired at an average price of $7.41 per share, with a total value of $951,636.66.
• On Wednesday, November 19th, Jan Stahlberg purchased 240,352 shares of DiaMedica Therapeutics stock. The shares were bought at an average cost of $7.21 per share, for a total transaction of $1,732,937.92.
• On Tuesday, November 18th, Jan Stahlberg acquired 182,882 shares of DiaMedica Therapeutics stock. The shares were bought at an average price of $6.75 per share, for a total transaction of $1,234,453.50.
• On Monday, November 17th, Jan Stahlberg acquired 187,393 shares of DiaMedica Therapeutics stock. The stock was bought at an average cost of $6.52 per share, with a total value of $1,221,802.36.

DiaMedica Therapeutics Stock Down 0.2%

Shares of NASDAQ:DMAC traded down $0.02 during trading on Monday, reaching $8.76. 374,509 shares of the company traded hands, compared to its average volume of 251,874. The firm has a market capitalization of $456.22 million, a PE ratio of -12.34 and a beta of 1.31. DiaMedica Therapeutics, Inc. has a 52 week low of $3.19 and a 52 week high of $9.23. The company’s 50 day moving average is $7.11 and its two-hundred day moving average is $5.70.

DiaMedica Therapeutics (NASDAQ:DMAC) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). As a group, research analysts anticipate that DiaMedica Therapeutics, Inc. will post -0.59 EPS for the current year.

Wall Street Analyst Weigh In

DMAC has been the subject of several analyst reports. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of DiaMedica Therapeutics in a research report on Friday, August 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research note on Wednesday, October 8th. TD Cowen assumed coverage on shares of DiaMedica Therapeutics in a research report on Thursday, October 30th. They set a “buy” rating for the company. Cantor Fitzgerald assumed coverage on DiaMedica Therapeutics in a report on Friday, November 14th. They issued an “overweight” rating on the stock. Finally, Cowen began coverage on DiaMedica Therapeutics in a research note on Thursday, October 30th. They issued a “buy” rating on the stock. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, DiaMedica Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $12.33.

Institutional Trading of DiaMedica Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. acquired a new position in shares of DiaMedica Therapeutics during the third quarter worth $27,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of DiaMedica Therapeutics during the 2nd quarter valued at $29,000. Bank of America Corp DE grew its position in DiaMedica Therapeutics by 3,710.3% during the 2nd quarter. Bank of America Corp DE now owns 8,497 shares of the company’s stock worth $33,000 after acquiring an additional 8,274 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in DiaMedica Therapeutics in the 2nd quarter worth about $49,000. Finally, Invesco Ltd. acquired a new position in DiaMedica Therapeutics in the 2nd quarter worth about $54,000. Institutional investors own 10.12% of the company’s stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.